BCHE and early-onset autosomal dominant Alzheimer disease: This tipping point is already in a problematic territory, if cholinesterase inhibitors are used in mild cognitive impairment [30], and galantamine would certainly not be appropriate for minor disorders unless systemic exposure is significantly lower than with Alzheimer’s disease.